REDWOOD CITY, Calif., July 18 /PRNewswire-FirstCall/ -- Genomic Health, Inc. today announced that during the Blue Cross and Blue Shield Association Medical Advisory Panel meeting on June 28, 2007, the panel concluded that use of Genomic Health’s Oncotype DX breast cancer assay to inform decision making about adjuvant chemotherapy meets the Blue Cross and Blue Shield Association Technology Evaluation Center (TEC) criteria for women with estrogen receptor-positive, node-negative, tamoxifen-treated breast cancer. The decision is posted at http://www.bcbs.com/betterknowledge/tec/press/actions-taken-by-the-medical- 1.html.
“The conclusion that the use of Oncotype DX to inform decision making about adjuvant chemotherapy meets TEC criteria is a substantial step forward for the field of personalized medicine,” said Randy Scott, Ph.D., chairman and chief executive officer of Genomic Health. “This assessment affirms our belief that clinical evidence is the foundation for improving treatment decisions and strongly supports the clinical utility of Oncotype DX.”
The Technology Evaluation Center
Founded in 1985 by the Blue Cross and Blue Shield Association, the Technology Evaluation Center pioneered the development of scientific criteria for assessing medical technologies through comprehensive reviews of clinical evidence. TEC operates as part of the Association’s Office of Clinical Affairs and its assessments are scientific opinions, provided solely for informational purposes.
About Oncotype DX
Oncotype DX represents the first diagnostic multi-gene expression test service commercially available that has clinical evidence validating its ability to predict the likelihood of breast cancer recurrence, the likelihood of patient survival within 10 years of diagnosis and the likelihood of chemotherapy benefit. Oncotype DX has been extensively evaluated in multiple independent studies involving more than 2,600 breast cancer patients, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. To date, over 5,500 physicians have ordered a cumulative total of more than 27,000 tests and approximately 125 million lives are now covered by reimbursement contracts and agreements. For more information about Oncotype DX, please visit http://www.oncotypedx.com.
About Genomic Health Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first test, Oncotype DX which has been shown to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit in a large portion of early-stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit http://www.genomichealth.com. Genomic Health, the Genomic Health logo and Oncotype DX are our trademarks or registered trademarks.
Genomic Health, Inc.
CONTACT: Investors, Brad Cole, +1-650-569-2281,investors@genomichealth.com, or media, Emily Faucette, +1-650-569-2824,media@genomichealth.com, both of Genomic Health
